Keros Therapeutics (KROS) Stock Forecast & Price Target

$56.62 -3.73 (-6.18%)

(As of 11/15/2024 ET)

Keros Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
0

Buy
12

Based on 12 Wall Street analysts who have issued ratings for Keros Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 12 have given a buy rating for KROS.

Consensus Price Target

$88.89
56.99% Upside

According to the 12 analysts' twelve-month price targets for Keros Therapeutics, the average price target is $88.89. The highest price target for KROS is $105.00, while the lowest price target for KROS is $60.00. The average price target represents a forecasted upside of 56.99% from the current price of $56.62.

KROS Analyst Ratings Over Time

Type	Current Forecast 11/17/23 to 11/16/24	1 Month Ago 10/18/23 to 10/17/24	3 Months Ago 8/19/23 to 8/18/24	1 Year Ago 11/17/22 to 11/17/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	10 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$88.89	$89.11	$92.17	$93.20
Forecasted Upside	56.99% Upside	45.87% Upside	102.39% Upside	207.79% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Do this if you missed cheap Bitcoin (Ad)

Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this... Because a new blockchain is taking the world by storm… It’s seeing rapid adoption amongst crypto fans… And just now starting to break into the mainstream. While I cannot promise future returns or against losses… This might not just be another chance at Bitcoin-like gains… It could be EVEN bigger. But this market is moving fast… So if you want a shot at getting in on what could be the ground floor

Click Here for Details.

KROS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KROS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Keros Therapeutics Stock vs. The Competition

Type	Keros Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	56.99% Upside	28,534.42% Upside	9.87% Upside
News Sentiment Rating	Neutral News See Recent KROS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	Wedbush 4 of 5 stars	Y. Zhong Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$84.00	+24.65%
11/7/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+50.49%
11/5/2024	Jefferies Financial Group 2 of 5 stars		Initiated Coverage	Buy
10/24/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
10/16/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$77.00	+27.50%
9/23/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$96.00	+72.04%
Let’s be blunt (Ad) Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now
9/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$81.00 ➝ $76.00	+37.09%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$102.00	+119.45%
6/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+122.22%
3/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$105.00	+59.60%
2/21/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$60.00	+68.97%
2/14/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
2/14/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
12/13/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$95.00 ➝ $105.00	+121.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:36 PM ET.

KROS Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Keros Therapeutics is $88.89, with a high forecast of $105.00 and a low forecast of $60.00.
: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KROS shares.
: According to analysts, Keros Therapeutics's stock has a predicted upside of 56.99% based on their 12-month stock forecasts.
: Over the previous 90 days, Keros Therapeutics's stock had 1 upgrade by analysts.
: Keros Therapeutics has been rated by research analysts at Bank of America, Cantor Fitzgerald, Guggenheim, HC Wainwright, Jefferies Financial Group, Scotiabank, and Wedbush in the past 90 days.
: Analysts like Keros Therapeutics more than other "medical" companies. The consensus rating for Keros Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KROS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Do this if you missed cheap Bitcoin (Ad)

Click Here for Details.

This page (NASDAQ:KROS) was last updated on 11/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Stock Forecast & Price Target